Thus, rapamycin‐treatment may be viewed as a double‐edged sword: Many of the benefits of rapamycin‐treatment may result from rapamycin‐induced reductions of insulin secretion, even in the context of hyperglycemia and hypertriglyceridemia, yet treatment of individuals with specific insulin signaling impairments (Friesen et al., 2016) or antecedent diminished pancreatic function (Reifsnyder et al., 2016) can be counterproductive. The gene discussed is INS; the disease is Hyperglycemia.